Safety & Interactions

Safety profile, bleeding risk, interaction cautions, and practical oncology considerations for aspirin

Aspirin has a familiar safety profile.

Cancer settings still change the risk picture.

This should be treated as a medication decision, not a casual add-on.

General tolerability

Common issues include:

stomach irritation
reflux or dyspepsia
easy bruising

More serious concerns include:

gastrointestinal bleeding, which can occur without warning pain
haemorrhagic complications in already fragile patients
interaction-related bleeding risk

Low-dose aspirin does not show a strong fatal-bleeding signal in many trials.

That is reassuring. It does not mean there is no individual risk.

Practical cautions

Risk factor	Why it matters
Prior ulcer or GI disease	Raises the risk of GI bleeding.
Older age	Makes the benefit-risk balance less favourable in general prevention settings.
Anticoagulants such as warfarin or rivaroxaban	Adds bleeding risk and needs clinician review.
Other NSAIDs such as ibuprofen or naproxen	Raises GI risk and complicates daily aspirin use.
Some chemotherapy regimens	Thrombocytopenia or mucosal injury can make bleeding more clinically important.
Alcohol use	Can worsen gastric irritation and bleeding risk.

How to interpret interaction evidence

Cell and laboratory findings can identify a possible interaction. They do not confirm the same effect occurs in people.

Read interaction claims alongside human pharmacokinetic and clinical evidence. See Drug Interaction Evidence and CYP Enzymes for the evidence hierarchy and practical questions to ask.

Clinical positioning

Aspirin deserves the same review as any other active drug.

The case for discussion is strongest where there is real biomarker or syndrome context, such as PIK3CA-mutated colorectal cancer or Lynch syndrome.

For broad primary prevention in healthy older adults, recent evidence does not support low-dose aspirin as a general cancer-prevention strategy.

Practical takeaway

The main safety issue is bleeding.

The main interaction issue is stacking aspirin with other drugs that also raise bleeding risk.

If aspirin is being considered during active treatment, the most useful questions are:

Is bleeding risk already elevated by the cancer, the treatment, or current labs?
Is the patient also using an anticoagulant, NSAID, or other drug that shifts the balance?
Is there a tumour subtype or syndrome where aspirin has a stronger evidence base?

Key References

García Rodríguez LA et al. (2011). Long Term Use of Aspirin and the Risk of Gastrointestinal Bleeding (dose-dependent risk; multivariate RR 1.43; highest with >14 tablets/week). BMJ 343:d5225. https://pmc.ncbi.nlm.nih.gov/articles/PMC3086018/[^45]
Valkhoff VE et al. (2016). Bleeding Risk with Long-Term Low-Dose Aspirin (NSAIDs, clopidogrel, SSRIs all increase bleeding; PPI use protective). PLOS ONE 11(8):e0160046. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160046[^46]
Lanas A et al. (2007). Association between aspirin and upper gastrointestinal complications: systematic review. Aliment Pharmacol Ther 26(2):187–202. https://pmc.ncbi.nlm.nih.gov/articles/PMC2014603/[^47]
Bhatt DL et al. (2018). Helicobacter pylori doubles bleeding risk in aspirin users (co-presence of H. pylori >2× risk of upper GI bleed). RACGP News GP Sep 2018. https://www1.racgp.org.au/newsgp/clinical/aspirin-doubles-bleeding-risk-for-people-with-comm[^48]

ASPREE Investigator Group (2021). Aspirin Use With Cancer Incidence and Survival (ASPREE trial: increased cancer-associated death in elderly ≥65 with late-stage disease — important safety caveat). JAMA Network Open 4(1):e2033622. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775219[^7]

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.